Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Penka

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Acta Medica Austriaca|June 8, 2002
Interleukin-2 activation of haematopoietic stem cellsR Hájek, Z Korístek, J Vinklárková, et al.
Neoplasma|July 13, 2011
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patientsJ Halamkova, I Kiss, Z Pavlovsky, et al.
Neoplasma|September 8, 2011
Prognostic significance of morphological assessment of plasma cells in multiple myelomaM Al-Sahmani, I Trnavska, S Sevcikova, et al.
Vnitrni Lekarstvi|March 23, 2011
[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]J Schwarz, M Penka, V Campr, et al.
Neoplasma|December 25, 2012
Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patientsJ Halamkova, I Kiss, Z Pavlovsky, et al.
Vnitrni Lekarstvi|April 3, 2012
[Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ]M Penka, J Schwarz, V Campr, et al.
Casopis Lekaru Ceskych|September 16, 2005
[Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma]J Smejkalová, V Vranová, A Oltová, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|September 15, 2017
Biomarkers in Immunoglobulin Light Chain AmyloidosisZ Kufová, T Sevcikova, K Growkova, et al.
Vnitrni Lekarstvi|September 11, 2008
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]M Penka, J Schwarz, T Pavlík, et al.
Leukemia|July 27, 2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusB Kubesova, S Pavlova, J Malcikova, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Acta Medica Austriaca|June 8, 2002
Interleukin-2 activation of haematopoietic stem cellsR Hájek, Z Korístek, J Vinklárková, et al.
Neoplasma|July 13, 2011
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patientsJ Halamkova, I Kiss, Z Pavlovsky, et al.
Neoplasma|September 8, 2011
Prognostic significance of morphological assessment of plasma cells in multiple myelomaM Al-Sahmani, I Trnavska, S Sevcikova, et al.
Vnitrni Lekarstvi|March 23, 2011
[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]J Schwarz, M Penka, V Campr, et al.
Neoplasma|December 25, 2012
Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patientsJ Halamkova, I Kiss, Z Pavlovsky, et al.
Vnitrni Lekarstvi|April 3, 2012
[Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ]M Penka, J Schwarz, V Campr, et al.
Casopis Lekaru Ceskych|September 16, 2005
[Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma]J Smejkalová, V Vranová, A Oltová, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|September 15, 2017
Biomarkers in Immunoglobulin Light Chain AmyloidosisZ Kufová, T Sevcikova, K Growkova, et al.
Vnitrni Lekarstvi|September 11, 2008
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]M Penka, J Schwarz, T Pavlík, et al.
Leukemia|July 27, 2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusB Kubesova, S Pavlova, J Malcikova, et al.
Pageof 11